SEC Tracker
Get the app

Longeveron LGVN

Longeveron sees director resignation

Item 5.02 Executive or director change

Form
8-K
Filed
Importance
Major
  1. Ms. Ursula Ungaro resigned from Longeveron's Board of Directors on November 1, 2026
  2. Resignation was due to personal health issues
  3. Ms. Ungaro was on multiple committees including Audit and Compensation

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Longeveron files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

The reading, claim by claim

  1. Her resignation was due to personal health issues, and she indicated no disagreement with the Company's operations, policies, or practices.
  2. The filing was signed by Stephen Willard, the Company's Chief Executive Officer.
  3. The Form 8-K includes details about the departure of directors and certain officers, as well as the election of directors and appointment of certain officers.
  4. The filing was made in accordance with the requirements of the Securities Exchange Act of 1934.

4 of 5 claims matched the filing text.

Not found in the filing text

  • It also covers compensatory arrangements of certain officers.

For perspective, checked against its own source

From the 10-Q for the quarter ended June 30, 2026

  • In its 10-Q for the quarter ended June 30, 2026, Longeveron Inc. reported revenue of $287,000.
  • The Company had a net income of -$6.1 million for the quarter.
  • The gross margin was 63.4%, and revenue decreased by 9.2% compared to the same period a year earlier.

From the filing

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Ap

Item3

5.02.3 3Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.3

(b)

On November 1, 2026, Ms. Ursula Ungaro provided Longeveron Inc. (the "Company") with notice of her immediate resignation from the Company's Board of Directors and its Audit Committee, Compensation Committee, Nominating and Corporate Governance Committee, and Special Committee. Ms. Ungaro indicated that her decision to resign was due to personal health issues and not the result of any disagreement with the Company on any matter related to the Company's operations, policies, or practices.1

1

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.4

LONGEVERON INC.

Date: November 5, 2026

/s/2

Stephen Willard2

Name:2

Stephen Willard2

Title:2

Chief Executive Officer2

2

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Lipocine LPCN public float $16M, Jun 30, 2025
  2. Marker Therapeutics MRKR public float $17M, Jun 30, 2025
  3. CalciMedica CALC public float $16M, Jun 30, 2025
  4. Ernexa Therapeutics ERNA public float $18M, Jun 30, 2025
  5. Charlie's Holdings CHUC public float $18M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.